Molecular characterization of macrolide resistance determinants [erm(B) and mef(A)] in Streptococcus pneumoniae and viridans group streptococci (VGS) isolated from adult patients with cystic fibrosis (CF)

Objectives Although long-term use of azithromycin has shown a significant clinical improvement for patients with cystic fibrosis (CF), its long-term effect on the susceptibility of commensal flora within CF airways has not yet been examined. We therefore suggest that long-term use of azithromycin in...

Full description

Saved in:
Bibliographic Details
Published inJournal of antimicrobial chemotherapy Vol. 64; no. 3; pp. 501 - 506
Main Authors Tazumi, Akihiro, Maeda, Yasunori, Goldsmith, Colin E., Coulter, Wilson A., Mason, Charlene, Millar, B. Cherie, McCalmont, Mark, Rendall, Jackie, Elborn, J. Stuart, Matsuda, Motoo, Moore, John E.
Format Journal Article
LanguageEnglish
Published Oxford Oxford University Press 01.09.2009
Oxford Publishing Limited (England)
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Objectives Although long-term use of azithromycin has shown a significant clinical improvement for patients with cystic fibrosis (CF), its long-term effect on the susceptibility of commensal flora within CF airways has not yet been examined. We therefore suggest that long-term use of azithromycin increases macrolide resistance in commensal streptococci. Methods Erythromycin susceptibility in naturally colonizing viridans group streptococci (VGS) was characterized, as well as macrolide resistance gene determinants through sequence analysis, in pneumococci (n = 15) and VGS [n = 84; i.e. Streptococcus salivarius (n = 30), Streptococcus mitis (n = 17), Streptococcus sanguinis (n = 11), Streptococcus oralis (n = 10), Streptococcus parasanguinis (n = 6), Streptococcus gordonii (n = 3), Streptococcus infantis (n = 3), Streptococcus cristatus (n = 2), Streptococcus anginosus (n = 1) and Streptococcus australis (n = 1)] isolated from sputum from 24 adult CF patients, who were on oral azithromycin therapy for at least the previous 7 months. Results Almost three-quarters of isolates (74; 74.7%) were resistant to erythromycin, whilst a further 15 (15.2%) had reduced susceptibility, leaving only 10 (10.1%) isolates susceptible to erythromycin. The majority (89.8%) were not susceptible to erythromycin, as demonstrated by possession of the erm(B) gene in 25/99 (25.3%), the mef(A) gene in 1/99 (1.0%), the mef(E) gene in 75/99 (75.8%) and both erm(B) and mef(E) genes simultaneously in 11/99 (11.1%). These results indicate that genotypic resistance for macrolides is common in VGS in adult CF patients, with efflux being over three times more frequent. Conclusions Long-term treatment with azithromycin in CF patients may reduce antibiotic susceptibility in commensal VGS, where these organisms may potentially act as a reservoir of macrolide resistance determinants for newly acquired and antibiotic-susceptible pathogens.
AbstractList Although long-term use of azithromycin has shown a significant clinical improvement for patients with cystic fibrosis (CF), its long-term effect on the susceptibility of commensal flora within CF airways has not yet been examined. We therefore suggest that long-term use of azithromycin increases macrolide resistance in commensal streptococci. Erythromycin susceptibility in naturally colonizing viridans group streptococci (VGS) was characterized, as well as macrolide resistance gene determinants through sequence analysis, in pneumococci (n = 15) and VGS [n = 84; i.e. Streptococcus salivarius (n = 30), Streptococcus mitis (n = 17), Streptococcus sanguinis (n = 11), Streptococcus oralis (n = 10), Streptococcus parasanguinis (n = 6), Streptococcus gordonii (n = 3), Streptococcus infantis (n = 3), Streptococcus cristatus (n = 2), Streptococcus anginosus (n = 1) and Streptococcus australis (n = 1)] isolated from sputum from 24 adult CF patients, who were on oral azithromycin therapy for at least the previous 7 months. Almost three-quarters of isolates (74; 74.7%) were resistant to erythromycin, whilst a further 15 (15.2%) had reduced susceptibility, leaving only 10 (10.1%) isolates susceptible to erythromycin. The majority (89.8%) were not susceptible to erythromycin, as demonstrated by possession of the erm(B) gene in 25/99 (25.3%), the mef(A) gene in 1/99 (1.0%), the mef(E) gene in 75/99 (75.8%) and both erm(B) and mef(E) genes simultaneously in 11/99 (11.1%). These results indicate that genotypic resistance for macrolides is common in VGS in adult CF patients, with efflux being over three times more frequent. Long-term treatment with azithromycin in CF patients may reduce antibiotic susceptibility in commensal VGS, where these organisms may potentially act as a reservoir of macrolide resistance determinants for newly acquired and antibiotic-susceptible pathogens.
Objectives Although long-term use of azithromycin has shown a significant clinical improvement for patients with cystic fibrosis (CF), its long-term effect on the susceptibility of commensal flora within CF airways has not yet been examined. We therefore suggest that long-term use of azithromycin increases macrolide resistance in commensal streptococci.Methods Erythromycin susceptibility in naturally colonizing viridans group streptococci (VGS) was characterized, as well as macrolide resistance gene determinants through sequence analysis, in pneumococci (n=15) and VGS [n=84; i.e. Streptococcus salivarius (n=30), Streptococcus mitis (n=17), Streptococcus sanguinis (n=11), Streptococcus oralis (n=10), Streptococcus parasanguinis (n=6), Streptococcus gordonii (n=3), Streptococcus infantis (n=3), Streptococcus cristatus (n=2), Streptococcus anginosus (n=1) and Streptococcus australis (n=1)] isolated from sputum from 24 adult CF patients, who were on oral azithromycin therapy for at least the previous 7 months.Results Almost three-quarters of isolates (74; 74.7%) were resistant to erythromycin, whilst a further 15 (15.2%) had reduced susceptibility, leaving only 10 (10.1%) isolates susceptible to erythromycin. The majority (89.8%) were not susceptible to erythromycin, as demonstrated by possession of the erm(B) gene in 25/99 (25.3%), the mef(A) gene in 1/99 (1.0%), the mef(E) gene in 75/99 (75.8%) and both erm(B) and mef(E) genes simultaneously in 11/99 (11.1%). These results indicate that genotypic resistance for macrolides is common in VGS in adult CF patients, with efflux being over three times more frequent.Conclusions Long-term treatment with azithromycin in CF patients may reduce antibiotic susceptibility in commensal VGS, where these organisms may potentially act as a reservoir of macrolide resistance determinants for newly acquired and antibiotic-susceptible pathogens.
Objectives: Although long-term use of azithromycin has shown a significant clinical improvement for patients with cystic fibrosis (CF), its long-term effect on the susceptibility of commensal flora within CF airways has not yet been examined. We therefore suggest that long-term use of azithromycin increases macrolide resistance in commensal streptococci. Methods: Erythromycin susceptibility in naturally colonizing viridans group streptococci (VGS) was characterized, as well as macrolide resistance gene determinants through sequence analysis, in pneumococci (n = 15) and VGS [n = 84; i.e. Streptococcus salivarius (n = 30), Streptococcus mitis (n = 17), Streptococcus sanguinis (n = 11), Streptococcus oralis (n = 10), Streptococcus parasanguinis (n = 6), Streptococcus gordonii (n = 3), Streptococcus infantis (n = 3), Streptococcus cristatus (n = 2), Streptococcus anginosus (n = 1) and Streptococcus australis (n = 1)] isolated from sputum from 24 adult CF patients, who were on oral azithromycin therapy for at least the previous 7 months. Results: Almost three-quarters of isolates (74; 74.7%) were resistant to erythromycin, whilst a further 15 (15.2%) had reduced susceptibility, leaving only 10 (10.1%) isolates susceptible to erythromycin. The majority (89.8%) were not susceptible to erythromycin, as demonstrated by possession of the erm (B) gene in 25/99 (25.3%), the mef (A) gene in 1/99 (1.0%), the mef (E) gene in 75/99 (75.8%) and both erm (B) and mef (E) genes simultaneously in 11/99 (11.1%). These results indicate that genotypic resistance for macrolides is common in VGS in adult CF patients, with efflux being over three times more frequent. Conclusions: Long-term treatment with azithromycin in CF patients may reduce antibiotic susceptibility in commensal VGS, where these organisms may potentially act as a reservoir of macrolide resistance determinants for newly acquired and antibiotic-susceptible pathogens. [PUBLICATION ABSTRACT]
Objectives Although long-term use of azithromycin has shown a significant clinical improvement for patients with cystic fibrosis (CF), its long-term effect on the susceptibility of commensal flora within CF airways has not yet been examined. We therefore suggest that long-term use of azithromycin increases macrolide resistance in commensal streptococci. Methods Erythromycin susceptibility in naturally colonizing viridans group streptococci (VGS) was characterized, as well as macrolide resistance gene determinants through sequence analysis, in pneumococci (n = 15) and VGS [n = 84; i.e. Streptococcus salivarius (n = 30), Streptococcus mitis (n = 17), Streptococcus sanguinis (n = 11), Streptococcus oralis (n = 10), Streptococcus parasanguinis (n = 6), Streptococcus gordonii (n = 3), Streptococcus infantis (n = 3), Streptococcus cristatus (n = 2), Streptococcus anginosus (n = 1) and Streptococcus australis (n = 1)] isolated from sputum from 24 adult CF patients, who were on oral azithromycin therapy for at least the previous 7 months. Results Almost three-quarters of isolates (74; 74.7%) were resistant to erythromycin, whilst a further 15 (15.2%) had reduced susceptibility, leaving only 10 (10.1%) isolates susceptible to erythromycin. The majority (89.8%) were not susceptible to erythromycin, as demonstrated by possession of the erm(B) gene in 25/99 (25.3%), the mef(A) gene in 1/99 (1.0%), the mef(E) gene in 75/99 (75.8%) and both erm(B) and mef(E) genes simultaneously in 11/99 (11.1%). These results indicate that genotypic resistance for macrolides is common in VGS in adult CF patients, with efflux being over three times more frequent. Conclusions Long-term treatment with azithromycin in CF patients may reduce antibiotic susceptibility in commensal VGS, where these organisms may potentially act as a reservoir of macrolide resistance determinants for newly acquired and antibiotic-susceptible pathogens.
Author Elborn, J. Stuart
Tazumi, Akihiro
Moore, John E.
Rendall, Jackie
Coulter, Wilson A.
Millar, B. Cherie
McCalmont, Mark
Goldsmith, Colin E.
Mason, Charlene
Matsuda, Motoo
Maeda, Yasunori
Author_xml – sequence: 1
  givenname: Akihiro
  surname: Tazumi
  fullname: Tazumi, Akihiro
  organization: Northern Ireland Public Health Laboratory, Department of Bacteriology, Belfast City Hospital, Lisburn Road, Belfast BT9 7AD, Northern Ireland, UK
– sequence: 2
  givenname: Yasunori
  surname: Maeda
  fullname: Maeda, Yasunori
  organization: Northern Ireland Public Health Laboratory, Department of Bacteriology, Belfast City Hospital, Lisburn Road, Belfast BT9 7AD, Northern Ireland, UK
– sequence: 3
  givenname: Colin E.
  surname: Goldsmith
  fullname: Goldsmith, Colin E.
  organization: Northern Ireland Public Health Laboratory, Department of Bacteriology, Belfast City Hospital, Lisburn Road, Belfast BT9 7AD, Northern Ireland, UK
– sequence: 4
  givenname: Wilson A.
  surname: Coulter
  fullname: Coulter, Wilson A.
  organization: School of Dentistry, Queen's University of Belfast, Royal Group of Hospitals, Belfast, Northern Ireland, UK
– sequence: 5
  givenname: Charlene
  surname: Mason
  fullname: Mason, Charlene
  organization: School of Dentistry, Queen's University of Belfast, Royal Group of Hospitals, Belfast, Northern Ireland, UK
– sequence: 6
  givenname: B. Cherie
  surname: Millar
  fullname: Millar, B. Cherie
  organization: Northern Ireland Public Health Laboratory, Department of Bacteriology, Belfast City Hospital, Lisburn Road, Belfast BT9 7AD, Northern Ireland, UK
– sequence: 7
  givenname: Mark
  surname: McCalmont
  fullname: McCalmont, Mark
  organization: Northern Ireland Public Health Laboratory, Department of Bacteriology, Belfast City Hospital, Lisburn Road, Belfast BT9 7AD, Northern Ireland, UK
– sequence: 8
  givenname: Jackie
  surname: Rendall
  fullname: Rendall, Jackie
  organization: Northern Ireland Regional Adult Cystic Fibrosis Unit, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, Northern Ireland, UK
– sequence: 9
  givenname: J. Stuart
  surname: Elborn
  fullname: Elborn, J. Stuart
  organization: Northern Ireland Regional Adult Cystic Fibrosis Unit, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, Northern Ireland, UK
– sequence: 10
  givenname: Motoo
  surname: Matsuda
  fullname: Matsuda, Motoo
  organization: Laboratory for Molecular Biology, School of Environmental Health Sciences, Azabu University, Sagamihara 229, Japan
– sequence: 11
  givenname: John E.
  surname: Moore
  fullname: Moore, John E.
  email: jemoore@niphl.dnet.co.uk, Corresponding author. Northern Ireland Public Health Laboratory, Department of Bacteriology, Belfast City Hospital, Belfast BT9 7AD, Northern Ireland, UK. Tel: +44-28-9026-3554; Fax: +44-28-9026-3991; jemoore@niphl.dnet.co.uk
  organization: Northern Ireland Public Health Laboratory, Department of Bacteriology, Belfast City Hospital, Lisburn Road, Belfast BT9 7AD, Northern Ireland, UK
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21880147$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/19584106$$D View this record in MEDLINE/PubMed
BookMark eNp90dFu0zAUBuAIDbFucMMDIAtpqEUqs-M4Ti63irVIRVwUJgRCluMcM2-JHWwHGM_IQ-HRapW44Mrn4tM5v_wfZQfWWciypwS_Irimp9dSnbY3Q07og2xCihLPc1yTg2yCKWZzXjB6mB2FcI0xLllZPcoOSc2qguBykv1-6zpQYyc9UlfSSxXBm18yGmeR06iXyrvOtIA8BBOitApQCwn1xkobA_qcxun5DEnboh709Gz2BRmLNtHDEJ1ySo0BDRbG3lkj4a_7brxppQ3oq3fjgMLeGjS9XG5myATXyQgt0t71SLZjF9GQUsHdyR8mXiF1G6JRSJvGu5QMTRcXs8fZQy27AE9273H24eL1-8Vqvn63fLM4W89VUZRxrgnmWLesoK1sS8Y5q5ucVoWGmvICJJRVU2vCSaHKWumKk4bUjaypZnnJm5IeZy-2ewfvvo0QouhNUNB10oIbg8jTfkarOsHn_8BrN3qbsomc8JJTVrOEXm5R-uoQPGgxeNNLfysIFncFi1Sw2Bac8LPdxrHpod3TXaMJnOyADEp22qfKTLh3OakqTAq-d6mB_x-cb11qH37eS-lvRMrPmVh9_CQu-XK9Xm3OxZr-Ac4Oz6w
CODEN JACHDX
CitedBy_id crossref_primary_10_1016_j_jcf_2010_11_003
crossref_primary_10_2217_fmb_10_99
crossref_primary_10_3389_fpubh_2019_00196
crossref_primary_10_1093_jac_dks351
crossref_primary_10_1093_jac_dkt495
crossref_primary_10_1183_23120541_00720_2022
crossref_primary_10_1128_JCM_01563_10
crossref_primary_10_1128_JCM_06438_11
crossref_primary_10_1016_S0140_6736_14_61137_5
crossref_primary_10_1111_j_2041_1626_2011_00100_x
crossref_primary_10_1128_AAC_04219_14
crossref_primary_10_1016_j_jcf_2011_06_003
crossref_primary_10_1016_S1413_8670_12_70292_1
crossref_primary_10_1016_j_jcf_2012_01_002
crossref_primary_10_1128_CMR_00078_09
crossref_primary_10_1099_jmm_0_027573_0
crossref_primary_10_1016_j_jcf_2019_11_004
crossref_primary_10_1099_jmm_0_071050_0
crossref_primary_10_1038_s41390_021_01419_4
crossref_primary_10_1099_jmm_0_000172
crossref_primary_10_1097_MCP_0b013e328358d49a
crossref_primary_10_3390_microorganisms10122438
crossref_primary_10_3390_microorganisms10122316
Cites_doi 10.1191/1479972305cd066rs
10.1183/09031936.00163306
10.1128/AAC.43.9.2335
10.1128/JCM.42.6.2651-2657.2004
10.1128/JCM.40.5.1575-1580.2002
10.1128/JCM.40.9.3313-3318.2002
10.1016/j.ccm.2007.02.005
10.1093/jac/dki404
10.1099/ijs.0.02639-0
10.1053/srin.2002.31690
10.1093/jac/dkl014
10.1016/j.ijantimicag.2007.08.001
10.1073/pnas.0804326105
10.1093/jac/dkh219
ContentType Journal Article
Copyright The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org 2009
2009 INIST-CNRS
The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Copyright_xml – notice: The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org 2009
– notice: 2009 INIST-CNRS
– notice: The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
DBID BSCLL
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QL
7QO
7T7
7U7
7U9
8FD
C1K
FR3
H94
K9.
M7N
NAPCQ
P64
DOI 10.1093/jac/dkp213
DatabaseName Istex
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Bacteriology Abstracts (Microbiology B)
Biotechnology Research Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Toxicology Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Virology and AIDS Abstracts
Technology Research Database
Toxicology Abstracts
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
Nursing & Allied Health Premium
Biotechnology Research Abstracts
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
DatabaseTitleList MEDLINE
Engineering Research Database

Virology and AIDS Abstracts

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1460-2091
EndPage 506
ExternalDocumentID 1828866961
10_1093_jac_dkp213
19584106
21880147
10.1093/jac/dkp213
ark_67375_HXZ_V7GLLHSB_L
Genre Research Support, Non-U.S. Gov't
Journal Article
Feature
GroupedDBID ---
-E4
.2P
.GJ
.I3
.XZ
.ZR
0R~
18M
1TH
29J
2WC
3O-
4.4
482
48X
53G
5GY
5RE
5VS
5WA
5WD
6.Y
70D
AABZA
AACZT
AAJKP
AAJQQ
AAMVS
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAUQX
AAVAP
AAWDT
AAWTL
ABEJV
ABEUO
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABPTD
ABQLI
ABQNK
ABQTQ
ABSAR
ABSMQ
ABWST
ABXVV
ABZBJ
ACCCW
ACFRR
ACGFO
ACGFS
ACIWK
ACMRT
ACPQN
ACPRK
ACUFI
ACUTJ
ACUTO
ACYHN
ACZBC
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADQBN
ADRIX
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEHUL
AEJOX
AEKPW
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFNX
AFFZL
AFIYH
AFOFC
AFRAH
AFSHK
AFXAL
AFXEN
AFYAG
AGINJ
AGKEF
AGKRT
AGMDO
AGQXC
AGSYK
AGUTN
AHMBA
AHXPO
AI.
AIAGR
AIJHB
AJEEA
ALMA_UNASSIGNED_HOLDINGS
ALUQC
APIBT
APJGH
APWMN
AQDSO
AQKUS
ASPBG
ATGXG
ATTQO
AVNTJ
AVWKF
AXUDD
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BSCLL
BTRTY
BVRKM
BZKNY
C45
CAG
CDBKE
COF
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBS
ECGQY
EE~
EIHJH
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HH5
HVGLF
HW0
HZ~
IOX
J21
J5H
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
M-Z
M49
MBLQV
MHKGH
ML0
N9A
NGC
NOMLY
NOYVH
NTWIH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OBS
OCZFY
ODMLO
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
O~Y
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
QBD
R44
RD5
RHF
RNI
ROL
ROX
ROZ
RUSNO
RW1
RXO
RZF
RZO
TCURE
TEORI
TJX
TMA
TR2
UCJ
VH1
W8F
WOQ
X7H
Y6R
YAYTL
YKOAZ
YXANX
ZGI
ZKX
ZXP
~91
~A~
AASNB
AABJS
AABMN
AAESY
AAIYJ
AANRK
ABPTK
ACIMA
ADEIU
ADORX
ADQLU
AIKOY
AIMBJ
ALXQX
ASMCH
AWCFO
AZQFJ
BGYMP
BYORX
CASEJ
DPORF
DPPUQ
IQODW
OBFPC
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QL
7QO
7T7
7U7
7U9
8FD
C1K
FR3
H94
K9.
M7N
NAPCQ
P64
ID FETCH-LOGICAL-c446t-f1070fd543dad657759b2384fe9374eae68b9f1714c69cf871b19ba93f5267b63
ISSN 0305-7453
IngestDate Wed Dec 04 10:59:37 EST 2024
Thu Oct 10 21:59:22 EDT 2024
Thu Nov 21 20:49:53 EST 2024
Tue Oct 15 23:39:23 EDT 2024
Sun Oct 22 16:08:58 EDT 2023
Wed Aug 28 03:24:35 EDT 2024
Wed Oct 30 09:36:52 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords azithromycin
commensal
antibiotic resistance
erythromycin
Human
Treatment resistance
Nucleotide sequence
Respiratory disease
Azithromycin
Metabolic diseases
Cystic fibrosis
Erythromycin
Macrolide
Genetic disease
Streptococcus pneumoniae
Streptococcaceae
Antibiotic
Bacteria
Micrococcales
Digestive diseases
Adult
Protein synthesis inhibitor
Antibacterial agent
Clinical isolate
Pancreatic disease
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c446t-f1070fd543dad657759b2384fe9374eae68b9f1714c69cf871b19ba93f5267b63
Notes ArticleID:dkp213
ark:/67375/HXZ-V7GLLHSB-L
istex:52311DD7496DA92AF80F38A999FF4AC2E04F5FD8
A. T. and Y. M. played an equal role in this study.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
OpenAccessLink https://academic.oup.com/jac/article-pdf/64/3/501/13759212/dkp213.pdf
PMID 19584106
PQID 217673595
PQPubID 32192
PageCount 6
ParticipantIDs proquest_miscellaneous_20705389
proquest_journals_217673595
crossref_primary_10_1093_jac_dkp213
pubmed_primary_19584106
pascalfrancis_primary_21880147
oup_primary_10_1093_jac_dkp213
istex_primary_ark_67375_HXZ_V7GLLHSB_L
PublicationCentury 2000
PublicationDate 2009-09-01
PublicationDateYYYYMMDD 2009-09-01
PublicationDate_xml – month: 09
  year: 2009
  text: 2009-09-01
  day: 01
PublicationDecade 2000
PublicationPlace Oxford
PublicationPlace_xml – name: Oxford
– name: England
PublicationTitle Journal of antimicrobial chemotherapy
PublicationTitleAlternate J Antimicrob Chemother
PublicationYear 2009
Publisher Oxford University Press
Oxford Publishing Limited (England)
Publisher_xml – name: Oxford University Press
– name: Oxford Publishing Limited (England)
References Arpin ( key 20170425183558_DKP213C16) 1999; 43
Uh ( key 20170425183558_DKP213C17) 2004; 53
Clinical and Laboratory Standards Institute ( key 20170425183558_DKP213C11) 2005
Ergin ( key 20170425183558_DKP213C14) 2006; 57
Sibley ( key 20170425183558_DKP213C8) 2008; 105
Amezaga ( key 20170425183558_DKP213C13) 2002; 40
McCormack ( key 20170425183558_DKP213C6) 2007; 30
key 20170425183558_DKP213C1
Täpp ( key 20170425183558_DKP213C9) 2003; 53
Phaff ( key 20170425183558_DKP213C7) 2006; 57
Giamarellos-Bourboulis ( key 20170425183558_DKP213C4) 2008; 31
Bell ( key 20170425183558_DKP213C5) 2005; 2
Millar ( key 20170425183558_DKP213C12) 2002; 40
Chen ( key 20170425183558_DKP213C10) 2004; 42
Rajan ( key 20170425183558_DKP213C2) 2002; 17
Artiles ( key 20170425183558_DKP213C15) 2007; 20
McArdle ( key 20170425183558_DKP213C3) 2007; 28
References_xml – volume: 2
  start-page: 85
  year: 2005
  ident: key 20170425183558_DKP213C5
  article-title: Macrolides in cystic fibrosis
  publication-title: Chron Respir Dis
  doi: 10.1191/1479972305cd066rs
  contributor:
    fullname: Bell
– volume: 30
  start-page: 487
  year: 2007
  ident: key 20170425183558_DKP213C6
  article-title: Daily versus weekly azithromycin in cystic fibrosis patients
  publication-title: Eur Respir J
  doi: 10.1183/09031936.00163306
  contributor:
    fullname: McCormack
– volume: 43
  start-page: 2335
  year: 1999
  ident: key 20170425183558_DKP213C16
  article-title: Incidence of mefA and mefE genes in viridans group streptococci
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.43.9.2335
  contributor:
    fullname: Arpin
– volume: 42
  start-page: 2651
  year: 2004
  ident: key 20170425183558_DKP213C10
  article-title: Identification of clinically relevant viridans group streptococci by sequence analysis of the 16S–23S ribosomal DNA spacer region
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.42.6.2651-2657.2004
  contributor:
    fullname: Chen
– ident: key 20170425183558_DKP213C1
– volume: 40
  start-page: 1575
  year: 2002
  ident: key 20170425183558_DKP213C12
  article-title: Risk assessment models and contamination management: implications for broad-range ribosomal DNA PCR as a diagnostic tool in medical bacteriology
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.40.5.1575-1580.2002
  contributor:
    fullname: Millar
– volume: 40
  start-page: 3313
  year: 2002
  ident: key 20170425183558_DKP213C13
  article-title: Molecular epidemiology of erythromycin resistance in Streptococcus pneumoniae isolates from blood and noninvasive sites
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.40.9.3313-3318.2002
  contributor:
    fullname: Amezaga
– volume: 28
  start-page: 347
  year: 2007
  ident: key 20170425183558_DKP213C3
  article-title: Macrolides in cystic fibrosis
  publication-title: Clin Chest Med
  doi: 10.1016/j.ccm.2007.02.005
  contributor:
    fullname: McArdle
– volume: 57
  start-page: 139
  year: 2006
  ident: key 20170425183558_DKP213C14
  article-title: Macrolide resistance mechanisms and in vitro susceptibility patterns of viridans group streptococci isolated from blood cultures
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dki404
  contributor:
    fullname: Ergin
– volume: 53
  start-page: 1861
  year: 2003
  ident: key 20170425183558_DKP213C9
  article-title: Phylogenetic relationships and genotyping of the genus Streptococcus by sequence determination of the RNase P RNA gene
  publication-title: rnpB. Int J Syst Evol Microbiol
  doi: 10.1099/ijs.0.02639-0
  contributor:
    fullname: Täpp
– volume: 17
  start-page: 47
  year: 2002
  ident: key 20170425183558_DKP213C2
  article-title: Pulmonary infections in patients with cystic fibrosis
  publication-title: Semin Respir Infect
  doi: 10.1053/srin.2002.31690
  contributor:
    fullname: Rajan
– volume: 57
  start-page: 741
  year: 2006
  ident: key 20170425183558_DKP213C7
  article-title: Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkl014
  contributor:
    fullname: Phaff
– volume: 20
  start-page: 317
  year: 2007
  ident: key 20170425183558_DKP213C15
  article-title: Phenotypes and genetic mechanisms of resistance to macrolides and lincosamides in viridans group streptococci
  publication-title: Rev Esp Quimioter
  contributor:
    fullname: Artiles
– volume: 31
  start-page: 12
  year: 2008
  ident: key 20170425183558_DKP213C4
  article-title: Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators
  publication-title: Int J Antimicrob Agents
  doi: 10.1016/j.ijantimicag.2007.08.001
  contributor:
    fullname: Giamarellos-Bourboulis
– volume: 105
  start-page: 15070
  year: 2008
  ident: key 20170425183558_DKP213C8
  article-title: A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0804326105
  contributor:
    fullname: Sibley
– volume-title: Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S15
  year: 2005
  ident: key 20170425183558_DKP213C11
  contributor:
    fullname: Clinical and Laboratory Standards Institute
– volume: 53
  start-page: 1095
  year: 2004
  ident: key 20170425183558_DKP213C17
  article-title: Antimicrobial susceptibility patterns and macrolide resistance genes of viridans group streptococci from blood cultures in Korea
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkh219
  contributor:
    fullname: Uh
SSID ssj0006568
Score 2.145675
Snippet Objectives Although long-term use of azithromycin has shown a significant clinical improvement for patients with cystic fibrosis (CF), its long-term effect on...
Objectives Although long-term use of azithromycin has shown a significant clinical improvement for patients with cystic fibrosis (CF), its long-term effect on...
Although long-term use of azithromycin has shown a significant clinical improvement for patients with cystic fibrosis (CF), its long-term effect on the...
Objectives: Although long-term use of azithromycin has shown a significant clinical improvement for patients with cystic fibrosis (CF), its long-term effect on...
SourceID proquest
crossref
pubmed
pascalfrancis
oup
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 501
SubjectTerms Adult
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
antibiotic resistance
Antibiotics
Antibiotics. Antiinfectious agents. Antiparasitic agents
azithromycin
Azithromycin - therapeutic use
Bacterial Proteins - genetics
Biological and medical sciences
commensal
Cystic fibrosis
Cystic Fibrosis - complications
Cystic Fibrosis - drug therapy
DNA, Bacterial - chemistry
DNA, Bacterial - genetics
Drug resistance
Drug Resistance, Bacterial
Errors of metabolism
erythromycin
Erythromycin - pharmacology
Humans
Macrolides - pharmacology
Medical sciences
Membrane Proteins - genetics
Metabolic diseases
Methyltransferases - genetics
Microbial Sensitivity Tests
Miscellaneous hereditary metabolic disorders
Molecular biology
Molecular Sequence Data
Pharmacology. Drug treatments
Sequence Analysis, DNA
Streptococcal Infections - microbiology
Streptococcus - drug effects
Streptococcus - genetics
Streptococcus - isolation & purification
Streptococcus anginosus
Streptococcus australis
Streptococcus gordonii
Streptococcus infantis
Streptococcus infections
Streptococcus mitis
Streptococcus oralis
Streptococcus parasanguinis
Streptococcus pneumoniae
Streptococcus salivarius
Streptococcus sanguinis
Title Molecular characterization of macrolide resistance determinants [erm(B) and mef(A)] in Streptococcus pneumoniae and viridans group streptococci (VGS) isolated from adult patients with cystic fibrosis (CF)
URI https://api.istex.fr/ark:/67375/HXZ-V7GLLHSB-L/fulltext.pdf
https://www.ncbi.nlm.nih.gov/pubmed/19584106
https://www.proquest.com/docview/217673595
https://search.proquest.com/docview/20705389
Volume 64
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1tb9MwELb2IiEkhGC8lcGwBJtademWJU6Wj-3eCmxo0rppgFDkJI4WRpuqaRDbb-RHcWfHSTu2afAlihMrTuJ7fGf77jlC3lkWM2M3BCDFIjJsMxLGZhAFBqgb4UWhG5sMo5EPPjndY_vDKTudmd2Z8FrKx0ErvLw2ruR_ehWuQb9ilOw_9Gz5ULgA59C_cIQehuOd-vhA57bF-N2Cd_mytAH7PMSUPBEmRsnQTEQMR5PuL8usAwWwMTu4OIBL6H0RQ7ENxWW2jWshuGs9HKcwbIZ51hwORA5fl3C16fAzGSUR6LqmjA2RcSdF3QQt15O9I3xuAj-Bo2ErQ1kk4Yemcy1i68ILZItuxjB1T5EgBXeWd_Uaxd-WM7x70k8kgxSym5yJfhFGVm4P9Phl3pd-Cu3z5CwZpdXCu4ikufyZZ_kgHSWl_1H6I8r0KtMWZjJq7rTKDRpMvq1kW9FbNtutqeWSyh9sfFsY5sSoCwOg4dqKwbgllFawnXUQPJVWTKsNRb5ewMOa0AGsaE4UJedaTaVYvL7zEI7R-XDDtCqNrL0Qrijq0n2Sj87RH89lfvf0i3_i7u3vd486_v4smUc-SEwhsf3-Y2mQOCoitPwyzdLrWWvQ_ppqfcoum8ch5peO-Xww5BkMGLHK9HLzVEyaZL1H5GEhEbStgPGYzIjBArl3UHiLLJCVQ8XLfrFKe1WYYbZKV-hhxdh-8YT8LoFErwKJpjEtgUQrINFJINGvcFrvNCiAggKE6u3GN5oM6BR4aAUeWU-Dh0rw0Enw0DpAp0E1cCgCh0rgUA0cisChCjhUA4fWt3YbT8nx7k5vq2sUaU6M0LadsRGboHbjiNlWxCOHuS7zAjCk7VjA1MEWXDibgRebrmmHjhfGm64ZmF7APStmG44bONYzMjdIB-IFodx0ApihmUywwA5kGrJQeGYAZj93YaJWI291J_tDxWbjKy8UywdR8JUo1MiK7P-yyk3yViNL8INufdLSlOyUVTeQBtK03RpZ1MLkFwNrBjddaI15rEbelHdB6-FWJh-INIcq8MvAVPNq5LmSwOolPJhSmevOy7t-xCK5X40Tr8jceJSL1zDRGAdLEkZ_APlbM7w
link.rule.ids 314,780,784,27924,27925
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular+characterization+of+macrolide+resistance+determinants+%5Berm%28B%29+and+mef%28A%29%5D+in+Streptococcus+pneumoniae+and+viridans+group+streptococci+%28VGS%29+isolated+from+adult+patients+with+cystic+fibrosis+%28CF%29&rft.jtitle=Journal+of+antimicrobial+chemotherapy&rft.au=Tazumi%2C+Akihiro&rft.au=Maeda%2C+Yasunori&rft.au=Goldsmith%2C+Colin+E.&rft.au=Coulter%2C+Wilson+A.&rft.date=2009-09-01&rft.pub=Oxford+University+Press&rft.issn=0305-7453&rft.eissn=1460-2091&rft.volume=64&rft.issue=3&rft.spage=501&rft.epage=506&rft_id=info:doi/10.1093%2Fjac%2Fdkp213&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_HXZ_V7GLLHSB_L
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0305-7453&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0305-7453&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0305-7453&client=summon